Time of Initiating Enzyme Replacement Therapy Affects Immune Abnormalities and Disease Severity in Patients with Gaucher Disease.

by Renuka Pudi Limgala, Chidima Ioanou, Matthew Plassmeyer, Mark Ryherd, Lina Kozhaya, Lauren Austin, Cem Abidoglu, Derya Unutmaz, Oral Alpan, Ozlem Goker-Alpan
Published 2016-01-01

SARS-CoV-2 specific antibody and neutralization assays reveal the wide range of the humoral immune response to virus

by Mikail Dogan, Lina Kozhaya, Lindsey Placek, Courtney Gunter, Mesut Yigit, Rachel Hardy, Matthew Plassmeyer, Paige Coatney, Kimberleigh Lillard, Zaheer Bukhari, Michael Kleinberg, Chelsea Hayes, Moshe Arditi, Ellen Klapper, Noah Merin, Bruce Tsan-Tang Liang, Raavi Gupta, Oral Alpan, Derya Unutmaz
Published 2021-01-01

CCR5 inhibition in critical COVID-19 patients decreases inflammatory cytokines, increases CD8 T-cells, and decreases SARS-CoV2 RNA in plasma by day 14

by Bruce K. Patterson, Harish Seethamraju, Kush Dhody, Michael J. Corley, Kazem Kazempour, Jay Lalezari, Alina P.S. Pang, Christopher Sugai, Eisa Mahyari, Edgar B. Francisco, Amruta Pise, Hallison Rodrigues, Helen L. Wu, Gabriela M. Webb, Byung S. Park, Scott Kelly, Nader Pourhassan, Alina Lelic, Lama Kdouh, Monica Herrera, Eric Hall, Benjamin N. Bimber, Matthew Plassmeyer, Raavi Gupta, Oral Alpan, Jane A. O’Halloran, Philip A. Mudd, Enver Akalin, Lishomwa C. Ndhlovu, Jonah B. Sacha
Published 2021-02-01